Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved GSK plc’s (NYSE:GSK) Penmenvy (Meningococcal Groups A, B, C, W, and Y ...

The CDC’s Advisory Committee on Immunization Practices is expected to provide recommendations on the appropriate use of Penmenvy at its meeting on February 26, 2025. The Food and Drug ...

The FDA has approved Penmenvy, a vaccine for individuals aged 10 to 25, targeting five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), which cause invasive meningococcal disease ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

According to the Virginia Department of Health, Virginia is not experiencing an outbreak of meningococcal disease, a serious ...

Penmenvy protects against meningococcal serotypes A, B, C, W and Y. CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent ...

The global meningococcal vaccine market is experiencing significant growth, driven by rising incidences of the disease worldwide. As of 2024, the market is estimated to be valued at USD 3,950.2 ...